Halozyme Therapeutics (HALO) Shares Outstanding (Weighted Average) (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $118.1 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $118.1 million, down 4.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $118.1 million (down 4.12% YoY), and the FY2025 annual result was $119.8 million, down 5.51% from the prior year.
• Shares Outstanding (Weighted Average) retreated to $118.1 million in Q1 2026 per HALO's latest filing, from $119.8 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $137.8 million in Q2 2022 and troughed at $118.1 million in Q1 2026.
• A 5-year average of $129.0 million and a median of $127.1 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) dropped 0.21% in 2022, then slipped 5.99% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $136.8 million in 2022, then slipped by 3.59% to $131.9 million in 2023, then decreased by 3.87% to $126.8 million in 2024, then fell by 5.51% to $119.8 million in 2025, then dropped by 1.42% to $118.1 million in 2026.
• Business Quant data shows HALO's Shares Outstanding (Weighted Average) at $118.1 million in Q1 2026, $119.8 million in Q4 2025, and $120.6 million in Q3 2025.